Semaglutide, the key component of medications like Ozempic and Wegovy, has recently shown promising results in improving heart health. The Semaglutide and Cardiovascular Outcomes (SELECT) trial, which involved over 17,600 overweight or obese adults with pre-existing cardiovascular disease, demonstrated that weekly injections of semaglutide can reduce the risk of stroke, heart attack, or fatal cardiovascular